Continued access to LP352 after a completed study
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This program lets people who have already finished a clinical trial of the study drug LP352 and are still getting benefit from it keep receiving it. It's designed for those with developmental epileptic encephalopathy (a type of epilepsy that starts in childhood and affects development).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a clinical trial of the drug LP352 (the study treatment) for developmental epileptic encephalopathy.
- Your doctor must confirm that LP352 is still helping your seizures (for example, fewer or less severe seizures).
- You must be tolerating LP352 well — no serious side effects that would make continuing unsafe.
- You cannot have stopped the LP352 trial early for any reason.
- You cannot have a new serious medical or mental health condition that would make the treatment unsafe or interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers continued access to the study drug rufinamide for people who completed an earlier study in Poland. It aims to provide ongoing treatment while collecting more safety information.
This study tests a new gene therapy called ION337 designed to treat Dravet syndrome, a severe childhood epilepsy caused by a SCN1A gene mutation. The therapy is given as a spinal fluid injection and aims to reduce seizures in children ages 2–12.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
This study lets people who were already getting benefit from a Lilly study treatment keep taking it after the main study ends, so doctors can continue to monitor their safety.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.